TITLE: IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells
Sharon S. Evans
Roswell Park Cancer Institute, Buffalo, New York, USA.
Phone: 716.845.3421; Fax: 716.845.1322; E-mail: firstname.lastname@example.org.
View this article at: http://www.jci.org/articles/view/44952?key=7389af36312eccfd1360
ONCOLOGY: Removing support for cancer cells
Pancreatic cancer is one of the most lethal cancers, with a 5-year survival rate of less than 5%. A team of researchers, led by Hideaki Ijichi, at the University of Tokyo, Japan, has now identified a new approach to reduce tumor progression in a mouse model of pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer in humans. Specifically, the team found that inhibiting the molecule Cxcr2 on the surface of stromal cells supporting the cancer cells reduced tumor progression and improved survival. The team therefore suggests that targeting tumor stromal cells, in particular by inhibiting Cxcr2, could provide a new approach for treating individuals with PDAC.
TITLE: Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Phone: 81.3.3815.544; Fax: 81.3.3814.0021; E-mail: email@example.com.
View this article at: http://www.jci.org/articles/view/42754?key=fb76126c4127b90a1e04
HEMATOLOGY: Triggering disease in a model of peripheral T cell lymphoma'/>"/>
|Contact: Karen Honey|
Journal of Clinical Investigation